Cargando…
An assessment of the tolerability of moxifloxacin 0.5% compared to azithromycin 1.0% in DuraSite(®)
This subject-masked, randomized, active and placebo-controlled study compared subjects’ perceptions of two antibiotic ophthalmic drops. One hundred and twenty-five healthy volunteers received two of the following solutions: moxifloxacin 0.5% ophthalmic solution (Vigamox(®), Alcon Laboratories, Inc.,...
Autores principales: | Granet, David, Lichtenstein, Steven J, Onofrey, Bruce, Katz, James A |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2704531/ https://www.ncbi.nlm.nih.gov/pubmed/19668531 |
Ejemplares similares
-
Fluoroquinolones compared to 1% azithromycin in DuraSite(®) for bacterial conjunctivitis
por: Lichtenstein, Steven J, et al.
Publicado: (2008) -
Azithromycin in DuraSite(®) for the treatment of blepharitis
por: Luchs, Jodi
Publicado: (2010) -
Effectiveness, tolerability and safety of azithromycin 1% in DuraSite(®) for acute bacterial conjunctivitis
por: McLean, Susannah, et al.
Publicado: (2010) -
Clinical development of 1% azithromycin in DuraSite(®), a topical azalide anti-infective for ocular surface therapy
por: Friedlaender, Mitchell H, et al.
Publicado: (2007) -
Response to correspondence from Lichtenstein and Granet Re: Fluoroquinolones compared to 1% azithromycin in DuraSite(®) for bacterial conjunctivitis
por: Friedlaender, Mitchell H, et al.
Publicado: (2008)